Having trouble accessing articles? Reset your cache.

Updated mipomersen safety data

Genzyme Corp. (NASDAQ:GENZ) and partner Isis Pharmaceuticals Inc. (NASDAQ:ISIS) reported additional data from the Phase III RADICHOL II trial to treat heterozygous familial hypercholesterolemia (heFH), including updated

Read the full 275 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE